The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT.
 
Meredith M. Regan
Honoraria - Bristol-Myers Squibb; WebMD
Consulting or Advisory Role - Bristol-Myers Squibb; Debiopharm Group (Inst); Ipsen (Inst); Tolmar
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); TerSera (Inst)
 
Samuel M. Niman
No Relationships to Disclose
 
Gini F. Fleming
Honoraria - Curio Science; Physicans' Education Resource
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Molecular Templates (Inst); Plexxikon (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie; TTC Oncology
 
Barbara Walley
Stock and Other Ownership Interests - Pfizer (I)
 
Giuseppe Viale
Honoraria - Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Dako; Menarini; MSD Oncology; Novartis; Roche/Genentech
Speakers' Bureau - Roche/Genentech
Research Funding - Cepheid (Inst); Dako/Agilent Technologies (Inst); Roche/Genentech; Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - Roche
 
Beat J. K. Thurlimann
Employment - Innomedica
Stock and Other Ownership Interests - Alcon; Merck; Novartis; Novartis (I); Roche; Roche (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; MSD; Pfizer; Pierre Fabre; Roche
Expert Testimony - AstraZeneca/Daiichi Sankyo
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support
 
Marco Colleoni
Research Funding - Roche (Inst)
 
Olivia Pagani
Consulting or Advisory Role - Debiopharm Group; Lilly; Novartis; Pfizer; Roche; Takeda
 
Prudence A. Francis
Honoraria - AstraZeneca; Novartis; Novartis
Travel, Accommodations, Expenses - Ipsen; Novartis